Sandbox Rim: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Rim Halaby (talk | contribs)
CMEUser, Bureaucrats, nocaptcha, Administrators
27,346 edits
No edit summary
Rim Halaby (talk | contribs)
CMEUser, Bureaucrats, nocaptcha, Administrators
27,346 edits
No edit summary
Line 3: Line 3:
| colspan="1" style="text-align:center; background:LightGreen"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class I]]
| colspan="1" style="text-align:center; background:LightGreen"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class I]]
|-
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' In AF patients, stroke risk must be assessed using the CHA2-DS2-VASc score, and bleeding risk assessed using the HAS-BLED score.2 Risk stratification is a dynamic process, and must be performed at regular intervals (i.e. on a yearly basis). ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: c]])''<nowiki>"</nowiki>
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' xxx. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: c]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Where adjusted dose VKA is used, good quality anticoagulation control is recommended, with a TTR >70%. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki>
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' xxx. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki>
|-
|-
|}
|}
Line 13: Line 13:
|colspan="1" style="text-align:center; background:LightCoral"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class III]]
|colspan="1" style="text-align:center; background:LightCoral"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class III]]
|-
|-
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Novel P2Y12 receptor inhibitors (prasugrel and ticagrelor) should not be part of a triple therapy regimen in patients with AF. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki>
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' xxx. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki>
|}
|}


Line 20: Line 20:
| colspan="1" style="text-align:center; background:LemonChiffon"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class IIa]]
| colspan="1" style="text-align:center; background:LemonChiffon"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' When VKA is given in combination with clopidogrel and/or low-dose aspirin, the dose intensity of VKA should be carefully regulated, with a target INR range of 2.0–2.5. ''([[JNC guidelines classification scheme#Evidence Quality Rating|Level of Evidence: Grade C]])''<nowiki>"</nowiki>
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' xxx ''([[JNC guidelines classification scheme#Evidence Quality Rating|Level of Evidence: Grade C]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' In a patient with AF and stable vascular disease (arbitrarily defined as being free from any acute ischaemic event or repeat revascularization for >1 year) the patient should be managed with OAC alone (i.e. whether NOAC or a VKA). ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade B]])''<nowiki>"</nowiki>
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' xxx. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade B]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.''' Radial access should be considered as the default for coronary angiography/intervention to minimize the risk of access related bleeding depending on operator expertise and preference. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade C]])''<nowiki>"</nowiki>
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.''' xxx. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade C]])''<nowiki>"</nowiki>
|-
|-
|}
|}
Line 32: Line 32:
| colspan="1" style="text-align:center; background:LemonChiffon"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class IIb]]
| colspan="1" style="text-align:center; background:LemonChiffon"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class IIb]]
|-
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Where aNOACis used in combination with clopidogrel and/or low-dose aspirin, the lower tested dose for stroke prevention in AF (that is, dabigatran 110 mg b.i.d., rivaroxaban 15 mg o.d. or apixaban 2.5 mg b.i.d.) may be considered (Prescribing information for edoxaban awaited.). ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade C]])''<nowiki>"</nowiki>
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' xxx. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade C]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' Newgeneration DES may be preferred over BMS in patients at low risk of bleeding (i.e. HAS-BLED 0–2). ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade C]])''<nowiki>"</nowiki>
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' xxx. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: Grade C]])''<nowiki>"</nowiki>
|-
|-
|}
|}

Revision as of 18:41, 4 September 2014

Class I
"1. xxx. (Level of Evidence: c)"
"2. xxx. (Level of Evidence: A)"
Class III
"1. xxx. (Level of Evidence: C)"
Class IIa
"1. xxx (Level of Evidence: Grade C)"
"2. xxx. (Level of Evidence: Grade B)"
"3. xxx. (Level of Evidence: Grade C)"
Class IIb
"1. xxx. (Level of Evidence: Grade C)"
"2. xxx. (Level of Evidence: Grade C)"
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_Rim&oldid=1017165"